

Gilead Sciences Announces Appointment of Kevin Young CBE as Chief Operating Officer and Martin Silverstein, MD as Executive Vice President, Strategy

May 24, 2016 4:30 PM ET

FOSTER CITY, Calif.--(BUSINESS WIRE)--May 24, 2016-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced two appointments to the company's senior leadership team. Kevin Young CBE has been appointed Chief Operating Officer, and Martin Silverstein, MD has been appointed Executive Vice President, Strategy. Both Mr. Young and Dr. Silverstein will report to John F. Milligan, PhD, President and Chief Executive Officer. The company also announced that Paul R. Carter, Executive Vice President, Commercial Operations, has decided to depart Gilead and pursue other opportunities.

As Chief Operating Officer, Mr. Young will assume responsibility for Gilead's worldwide commercial organization, and facilities and operations. From 2004 through 2014, Mr. Young served as Gilead's Executive Vice President of Commercial Operations. Since 2014, he has held the role of senior advisor to the company. Prior to Gilead, he spent more than 20 years in the biopharmaceutical industry, first with ICI Pharmaceuticals and subsequently with Amgen. Mr. Young has undergraduate and graduate degrees in Sports Science and Exercise from Liverpool and Nottingham, England. In 2011, he was appointed a Commander of The British Empire, one of Great Britain's highest civilian honors, in recognition of his "services to the healthcare and pharmaceutical industries."

"I am delighted to welcome Kevin back to Gilead in a full-time capacity. His contributions during his previous tenure, particularly his management of the introduction of eight novel therapies across diverse geographies, made a tremendous impact on the company. I have equally valued his continued engagement and significant contributions as an advisor to Gilead over the past two years," said Dr. Milligan. "Kevin's knowledge of Gilead's business, all aspects of commercial operations and our therapeutic areas of focus, his commitment to operational excellence, and his leadership capabilities make him an obvious choice for the role of Chief Operating Officer."

Dr. Silverstein will oversee Gilead's corporate development, commercial planning and alliance management functions. He previously held the role of Executive Vice President and Chief Strategy Officer at Anthem from April 2014 through December 2015. Prior to Anthem, Dr. Silverstein spent 28 years in roles of increasing responsibility at The Boston Consulting Group, including serving as Global Leader of its Health Care Practice, Senior Partner and Managing Director. He received a medical degree from Yale University, an MBA from Harvard Business School and a bachelor's degree from the University of Pennsylvania. He completed his internal medicine residency at Boston's Beth Israel Hospital and is board certified in Internal Medicine.

"I'm very pleased to welcome Marty to the Gilead team," commented Dr. Milligan. "His vast expertise in the healthcare sector, across biopharmaceuticals, pharmacy benefit management, health insurance and healthcare delivery, will be of great value to Gilead as we see the complexity of our business increase around the world. I'm looking forward to working with Marty and the rest of the company's senior leadership team to deliver continued growth and bring more medicines to more people around the world."

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

Gilead Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to

rely on these forward-looking statements. These and other risks are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

For more information on Gilead Sciences, please visit the company's website at www.gilead.com, follow Gilead on Twitter ([@GileadSciences](https://twitter.com/GileadSciences)) or call Gilead Public Affairs at 1-650-574-3000.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20160524006633/en/>

Source: Gilead Sciences, Inc.

Gilead Sciences, Inc.

Sung Lee, 650-524-7792 (Investors)

Amy Flood, 650-522-5643 (Media)